New research points to an entirely new approach for designing insulin-based pharmaceuticals. The approach could open the door for more personalized medications with fewer side effects for Type 1 Diabetes patients, say researchers.
New research points to an entirely new approach for designing insulin-based pharmaceuticals. The approach could open the door for more personalized medications with fewer side effects for Type 1 Diabetes patients, say researchers.